Showing results (261-270 of 284) with videos related to
Sort By:
Pageof 29
Journal of Glaucoma|April 19, 2021
Comparison of Outcomes of Glaucoma Drainage Implant Surgery With or Without Prior Failed TrabeculectomyEmily F Dawson, Nicole C Rosenberg, Alissa M Meyer, et al.Cell Metabolism|September 20, 2016
AMPK/α-Ketoglutarate Axis Dynamically Mediates DNA Demethylation in the Prdm16 Promoter and Brown AdipogenesisQiyuan Yang, Xingwei Liang, Xiaofei Sun, et al.Inorganic Chemistry|February 3, 2016
Synthesis of cis-[Cr(diimine)2(1-methylimidazole)2](3+) Complexes and an Investigation of Their Interaction with Mononucleotides and PolynucleotidesSarah K Goforth, Thomas W Gill, April E Weisbruch, et al.Antimicrobial Agents and Chemotherapy|December 3, 1999
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1J W Corbett, S S Ko, J D Rodgers, et al.The British Journal of Ophthalmology|August 18, 2017
Comparing glaucomatous disc change using stereo disc viewing and the MatchedFlicker programme in glaucoma experts and traineesJamie L Schaefer, Alissa M Meyer, Cooper D Rodgers, et al.Nature Communications|August 22, 2024
Structure of anellovirus-like particles reveal a mechanism for immune evasionShu-Hao Liou, Rajendra Boggavarapu, Noah R Cohen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severityPhillip C C Liu, Eian Caulder, Jun Li, et al.Journal of Medicinal Chemistry|May 23, 2000
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitorsJ W Corbett, S S Ko, J D Rodgers, et al.The Journal of Investigative Dermatology|June 17, 2011
Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammationJordan S Fridman, Peggy A Scherle, Robert Collins, et al.Blood|February 5, 2010
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsAlfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, et al.Pageof 29